Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
183
-
Total 13F shares, excl. options
-
84.1M
-
Shares change
-
+4.6M
-
Total reported value, excl. options
-
$3.15B
-
Value change
-
+$161M
-
Put/Call ratio
-
0.59
-
Number of buys
-
92
-
Number of sells
-
-89
-
Price
-
$37.48
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q1 2023
229 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q1 2023.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 183 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.1M shares
of 130M outstanding shares and own 64.67% of the company stock.
Largest 10 shareholders include FMR LLC (11.8M shares), RA CAPITAL MANAGEMENT, L.P. (7.29M shares), JANUS HENDERSON GROUP PLC (7.13M shares), VANGUARD GROUP INC (6.53M shares), BlackRock Inc. (5.08M shares), WELLINGTON MANAGEMENT GROUP LLP (3.24M shares), STATE STREET CORP (3.08M shares), Capital Research Global Investors (2.85M shares), Carlyle Group Inc. (1.92M shares), and Medicxi Ventures Management (Jersey) Ltd (1.46M shares).
This table shows the top 183 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.